Skip to main content
PMC home page
Clinical Molecular Pathology logoLink to Clinical Molecular Pathology
. 1995 Oct;48(5):M221–M238. doi: 10.1136/mp.48.5.m221

Biological indices in the assessment of breast cancer

A S-Y Leong 1,2, A K C Lee 1,2
PMCID: PMC407976  PMID: 16696013

Full text

PDF
M221

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abel K. J., Boehnke M., Prahalad M., Ho P., Flejter W. L., Watkins M., VanderStoep J., Chandrasekharappa S. C., Collins F. S., Glover T. W. A radiation hybrid map of the BRCA1 region of chromosome 17q12-q21. Genomics. 1993 Sep;17(3):632–641. doi: 10.1006/geno.1993.1383. [DOI] [PubMed] [Google Scholar]
  2. Adnane J., Gaudray P., Simon M. P., Simony-Lafontaine J., Jeanteur P., Theillet C. Proto-oncogene amplification and human breast tumor phenotype. Oncogene. 1989 Nov;4(11):1389–1395. [PubMed] [Google Scholar]
  3. Allred D. C., Clark G. M., Elledge R., Fuqua S. A., Brown R. W., Chamness G. C., Osborne C. K., McGuire W. L. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 1993 Feb 3;85(3):200–206. doi: 10.1093/jnci/85.3.200. [DOI] [PubMed] [Google Scholar]
  4. Allred D. C., Clark G. M., Molina R., Tandon A. K., Schnitt S. J., Gilchrist K. W., Osborne C. K., Tormey D. C., McGuire W. L. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol. 1992 Sep;23(9):974–979. doi: 10.1016/0046-8177(92)90257-4. [DOI] [PubMed] [Google Scholar]
  5. Allred D. C., Clark G. M., Tandon A. K., Molina R., Tormey D. C., Osborne C. K., Gilchrist K. W., Mansour E. G., Abeloff M., Eudey L. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol. 1992 Apr;10(4):599–605. doi: 10.1200/JCO.1992.10.4.599. [DOI] [PubMed] [Google Scholar]
  6. Andersen T. I., Holm R., Nesland J. M., Heimdal K. R., Ottestad L., Børresen A. L. Prognostic significance of TP53 alterations in breast carcinoma. Br J Cancer. 1993 Sep;68(3):540–548. doi: 10.1038/bjc.1993.383. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Anderson L. A., Friedman L., Osborne-Lawrence S., Lynch E., Weissenbach J., Bowcock A., King M. C. High-density genetic map of the BRCA1 region of chromosome 17q12-q21. Genomics. 1993 Sep;17(3):618–623. doi: 10.1006/geno.1993.1381. [DOI] [PubMed] [Google Scholar]
  8. Ariad S., Seymour L., Bezwoda W. R. Platelet-derived growth factor (PDGF) in plasma of breast cancer patients: correlation with stage and rate of progression. Breast Cancer Res Treat. 1991 Dec;20(1):11–17. doi: 10.1007/BF01833352. [DOI] [PubMed] [Google Scholar]
  9. Bacus S. S., Bacus J. W., Slamon D. J., Press M. F. HER-2/neu oncogene expression and DNA ploidy analysis in breast cancer. Arch Pathol Lab Med. 1990 Feb;114(2):164–169. [PubMed] [Google Scholar]
  10. Bacus S. S., Ruby S. G., Weinberg D. S., Chin D., Ortiz R., Bacus J. W. HER-2/neu oncogene expression and proliferation in breast cancers. Am J Pathol. 1990 Jul;137(1):103–111. [PMC free article] [PubMed] [Google Scholar]
  11. Barbareschi M., Leonardi E., Mauri F. A., Serio G., Dalla Palma P. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer. Am J Clin Pathol. 1992 Oct;98(4):408–418. doi: 10.1093/ajcp/98.4.408. [DOI] [PubMed] [Google Scholar]
  12. Barbareschi M., Leonardi E., Mauri F. A., Serio G., Dalla Palma P. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer. Am J Clin Pathol. 1992 Oct;98(4):408–418. doi: 10.1093/ajcp/98.4.408. [DOI] [PubMed] [Google Scholar]
  13. Barnes D. M., Bartkova J., Camplejohn R. S., Gullick W. J., Smith P. J., Millis R. R. Overexpression of the c-erbB-2 oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance? Eur J Cancer. 1992;28(2-3):644–648. doi: 10.1016/s0959-8049(05)80117-0. [DOI] [PubMed] [Google Scholar]
  14. Barnes D. M., Dublin E. A., Fisher C. J., Levison D. A., Millis R. R. Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum Pathol. 1993 May;24(5):469–476. doi: 10.1016/0046-8177(93)90158-d. [DOI] [PubMed] [Google Scholar]
  15. Barnes D. M., Lammie G. A., Millis R. R., Gullick W. L., Allen D. S., Altman D. G. An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. Br J Cancer. 1988 Oct;58(4):448–452. doi: 10.1038/bjc.1988.238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Bartkova J., Bartek J., Vojtesek B., Lukas J., Rejthar A., Kovarik J., Millis R. R., Lane D. P., Barnes D. M. Immunochemical analysis of the p53 oncoprotein in matched primary and metastatic human tumours. Eur J Cancer. 1993;29A(6):881–886. doi: 10.1016/s0959-8049(05)80431-9. [DOI] [PubMed] [Google Scholar]
  17. Berger M. S., Locher G. W., Saurer S., Gullick W. J., Waterfield M. D., Groner B., Hynes N. E. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res. 1988 Mar 1;48(5):1238–1243. [PubMed] [Google Scholar]
  18. Berns E. M., Klijn J. G., van Staveren I. L., Portengen H., Noordegraaf E., Foekens J. A. Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors. Eur J Cancer. 1992;28(2-3):697–700. doi: 10.1016/s0959-8049(05)80129-7. [DOI] [PubMed] [Google Scholar]
  19. Bevilacqua G., Sobel M. E., Liotta L. A., Steeg P. S. Association of low nm23 RNA levels in human primary infiltrating ductal breast carcinomas with lymph node involvement and other histopathological indicators of high metastatic potential. Cancer Res. 1989 Sep 15;49(18):5185–5190. [PubMed] [Google Scholar]
  20. Bhargava V., Thor A., Deng G., Ljung B. M., Moore D. H., 2nd, Waldman F., Benz C., Goodson W., 3rd, Mayall B., Chew K. The association of p53 immunopositivity with tumor proliferation and other prognostic indicators in breast cancer. Mod Pathol. 1994 Apr;7(3):361–368. [PubMed] [Google Scholar]
  21. Bianchi S., Paglierani M., Zampi G., Cardona G., Cataliotti L., Bonardi R., Ciatto S. Prognostic significance of c-erbB-2 expression in node negative breast cancer. Br J Cancer. 1993 Mar;67(3):625–629. doi: 10.1038/bjc.1993.114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Bonadonna G. Karnofsky memorial lecture. Conceptual and practical advances in the management of breast cancer. J Clin Oncol. 1989 Oct;7(10):1380–1397. doi: 10.1200/JCO.1989.7.10.1380. [DOI] [PubMed] [Google Scholar]
  23. Borg A., Baldetorp B., Fernö M., Killander D., Olsson H., Sigurdsson H. ERBB2 amplification in breast cancer with a high rate of proliferation. Oncogene. 1991 Jan;6(1):137–143. [PubMed] [Google Scholar]
  24. Borg A., Tandon A. K., Sigurdsson H., Clark G. M., Fernö M., Fuqua S. A., Killander D., McGuire W. L. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res. 1990 Jul 15;50(14):4332–4337. [PubMed] [Google Scholar]
  25. Borg A., Zhang Q. X., Alm P., Olsson H., Sellberg G. The retinoblastoma gene in breast cancer: allele loss is not correlated with loss of gene protein expression. Cancer Res. 1992 May 15;52(10):2991–2994. [PubMed] [Google Scholar]
  26. Bosari S., Lee A. K., DeLellis R. A., Wiley B. D., Heatley G. J., Silverman M. L. Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol. 1992 Jul;23(7):755–761. doi: 10.1016/0046-8177(92)90344-3. [DOI] [PubMed] [Google Scholar]
  27. Bosari S., Lee A. K., Viale G., Heatley G. J., Coggi G. Abnormal p53 immunoreactivity and prognosis in node-negative breast carcinomas with long-term follow-up. Virchows Arch A Pathol Anat Histopathol. 1992;421(4):291–295. doi: 10.1007/BF01660975. [DOI] [PubMed] [Google Scholar]
  28. Bosari S., Viale G., Bossi P., Maggioni M., Coggi G., Murray J. J., Lee A. K. Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas. J Natl Cancer Inst. 1994 May 4;86(9):681–687. doi: 10.1093/jnci/86.9.681. [DOI] [PubMed] [Google Scholar]
  29. Bowcock A. M., Anderson L. A., Friedman L. S., Black D. M., Osborne-Lawrence S., Rowell S. E., Hall J. M., Solomon E., King M. C. THRA1 and D17S183 flank an interval of < 4 cM for the breast-ovarian cancer gene (BRCA1) on chromosome 17q21. Am J Hum Genet. 1993 Apr;52(4):718–722. [PMC free article] [PubMed] [Google Scholar]
  30. Bowcock A. M., Hall J. M., Hebert J. M., King M. C. Exclusion of the retinoblastoma gene and chromosome 13q as the site of a primary lesion for human breast cancer. Am J Hum Genet. 1990 Jan;46(1):12–17. [PMC free article] [PubMed] [Google Scholar]
  31. Briffod M., Spyratos F., Tubiana-Hulin M., Pallud C., Mayras C., Filleul A., Rouëssé J. Sequential cytopunctures during preoperative chemotherapy for primary breast carcinoma. Cytomorphologic changes, initial tumor ploidy, and tumor regression. Cancer. 1989 Feb 15;63(4):631–637. doi: 10.1002/1097-0142(19890215)63:4<631::aid-cncr2820630405>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  32. Brocklehurst D., Wilde C. E., Finbow J. A., Brett R., Champion A. E., Dewhurst D. G. Relative importance of estrogen and progesterone receptor assays as prognostic indicators in primary breast cancer: a short-term study. Clin Chem. 1989 Feb;35(2):238–240. [PubMed] [Google Scholar]
  33. Bronzert D. A., Pantazis P., Antoniades H. N., Kasid A., Davidson N., Dickson R. B., Lippman M. E. Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines. Proc Natl Acad Sci U S A. 1987 Aug;84(16):5763–5767. doi: 10.1073/pnas.84.16.5763. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Bártek J., Bártková J., Vojtesek B., Stasková Z., Rejthar A., Kovarík J., Lane D. P. Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro. Int J Cancer. 1990 Nov 15;46(5):839–844. doi: 10.1002/ijc.2910460515. [DOI] [PubMed] [Google Scholar]
  35. Børresen A. L., Hovig E., Smith-Sørensen B., Malkin D., Lystad S., Andersen T. I., Nesland J. M., Isselbacher K. J., Friend S. H. Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations. Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8405–8409. doi: 10.1073/pnas.88.19.8405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Caleffi M., Teague M. W., Jensen R. A., Vnencak-Jones C. L., Dupont W. D., Parl F. F. p53 gene mutations and steroid receptor status in breast cancer. Clinicopathologic correlations and prognostic assessment. Cancer. 1994 Apr 15;73(8):2147–2156. doi: 10.1002/1097-0142(19940415)73:8<2147::aid-cncr2820730820>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  37. Casey G., Lo-Hsueh M., Lopez M. E., Vogelstein B., Stanbridge E. J. Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene. Oncogene. 1991 Oct;6(10):1791–1797. [PubMed] [Google Scholar]
  38. Casey G., Plummer S., Hoeltge G., Scanlon D., Fasching C., Stanbridge E. J. Functional evidence for a breast cancer growth suppressor gene on chromosome 17. Hum Mol Genet. 1993 Nov;2(11):1921–1927. doi: 10.1093/hmg/2.11.1921. [DOI] [PubMed] [Google Scholar]
  39. Cattoretti G., Becker M. H., Key G., Duchrow M., Schlüter C., Galle J., Gerdes J. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol. 1992 Dec;168(4):357–363. doi: 10.1002/path.1711680404. [DOI] [PubMed] [Google Scholar]
  40. Cattoretti G., Rilke F., Andreola S., D'Amato L., Delia D. P53 expression in breast cancer. Int J Cancer. 1988 Feb 15;41(2):178–183. doi: 10.1002/ijc.2910410204. [DOI] [PubMed] [Google Scholar]
  41. Charpin C., Devictor B., Bonnier P., Andrac L., Lavaut M. N., Allasia C., Piana L. Cathepsin D immunocytochemical assays in breast carcinomas: image analysis and correlation to prognostic factors. J Pathol. 1993 Aug;170(4):463–470. doi: 10.1002/path.1711700410. [DOI] [PubMed] [Google Scholar]
  42. Chevallier B., Heintzmann F., Mosseri V., Dauce J. P., Bastit P., Graic Y., Brunelle P., Basuyau J. P., Comoz M., Asselain B. Prognostic value of estrogen and progesterone receptors in operable breast cancer. Results of a univariate and multivariate analysis. Cancer. 1988 Dec 15;62(12):2517–2524. doi: 10.1002/1097-0142(19881215)62:12<2517::aid-cncr2820621211>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  43. Chou M. Y., Chang A. L., McBride J., Donoff B., Gallagher G. T., Wong D. T. A rapid method to determine proliferation patterns of normal and malignant tissues by H3 mRNA in situ hybridization. Am J Pathol. 1990 Apr;136(4):729–733. [PMC free article] [PubMed] [Google Scholar]
  44. Ciocca D. R., Fujimura F. K., Tandon A. K., Clark G. M., Mark C., Lee-Chen G. J., Pounds G. W., Vendely P., Owens M. A., Pandian M. R. Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. J Natl Cancer Inst. 1992 Aug 19;84(16):1279–1282. doi: 10.1093/jnci/84.16.1279. [DOI] [PubMed] [Google Scholar]
  45. Ciocca D. R., Fuqua S. A., Lock-Lim S., Toft D. O., Welch W. J., McGuire W. L. Response of human breast cancer cells to heat shock and chemotherapeutic drugs. Cancer Res. 1992 Jul 1;52(13):3648–3654. [PubMed] [Google Scholar]
  46. Clark G. M., Dressler L. G., Owens M. A., Pounds G., Oldaker T., McGuire W. L. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med. 1989 Mar 9;320(10):627–633. doi: 10.1056/NEJM198903093201003. [DOI] [PubMed] [Google Scholar]
  47. Clark G. M., McGuire W. L. Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res. 1991 Feb 1;51(3):944–948. [PubMed] [Google Scholar]
  48. Cline M. J., Battifora H., Yokota J. Proto-oncogene abnormalities in human breast cancer: correlations with anatomic features and clinical course of disease. J Clin Oncol. 1987 Jul;5(7):999–1006. doi: 10.1200/JCO.1987.5.7.999. [DOI] [PubMed] [Google Scholar]
  49. Coles C., Condie A., Chetty U., Steel C. M., Evans H. J., Prosser J. p53 mutations in breast cancer. Cancer Res. 1992 Oct 1;52(19):5291–5298. [PubMed] [Google Scholar]
  50. Courdi A., Héry M., Dahan E., Gioanni J., Abbes M., Monticelli J., Ettore F., Moll J. L., Namer M. Factors affecting relapse in node-negative breast cancer. A multivariate analysis including the labeling index. Eur J Cancer Clin Oncol. 1989 Feb;25(2):351–356. doi: 10.1016/0277-5379(89)90029-1. [DOI] [PubMed] [Google Scholar]
  51. Crawford L. V., Pim D. C., Bulbrook R. D. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer. 1982 Oct 15;30(4):403–408. doi: 10.1002/ijc.2910300404. [DOI] [PubMed] [Google Scholar]
  52. D'Errico A., Garbisa S., Liotta L. A., Castronovo V., Stetler-Stevenson W. G., Grigioni W. F. Augmentation of type IV collagenase, laminin receptor, and Ki67 proliferation antigen associated with human colon, gastric, and breast carcinoma progression. Mod Pathol. 1991 Mar;4(2):239–246. [PubMed] [Google Scholar]
  53. Daidone M. G., Silvestrini R., D'Errico A., Di Fronzo G., Benini E., Mancini A. M., Garbisa S., Liotta L. A., Grigioni W. F. Laminin receptors, collagenase IV and prognosis in node-negative breast cancers. Int J Cancer. 1991 Jun 19;48(4):529–532. doi: 10.1002/ijc.2910480409. [DOI] [PubMed] [Google Scholar]
  54. Davidoff A. M., Herndon J. E., 2nd, Glover N. S., Kerns B. J., Pence J. C., Iglehart J. D., Marks J. R. Relation between p53 overexpression and established prognostic factors in breast cancer. Surgery. 1991 Aug;110(2):259–264. [PubMed] [Google Scholar]
  55. Davidoff A. M., Kerns B. J., Iglehart J. D., Marks J. R. Maintenance of p53 alterations throughout breast cancer progression. Cancer Res. 1991 May 15;51(10):2605–2610. [PubMed] [Google Scholar]
  56. Deng G., Chen L. C., Schott D. R., Thor A., Bhargava V., Ljung B. M., Chew K., Smith H. S. Loss of heterozygosity and p53 gene mutations in breast cancer. Cancer Res. 1994 Jan 15;54(2):499–505. [PubMed] [Google Scholar]
  57. Devilee P., Cornelis R. S., Bootsma A., Bardoel A., van Vliet M., van Leeuwen I., Cleton F. J., de Klein A., Lindhout D., Vasen H. F. Linkage to markers for the chromosome region 17q12-q21 in 13 Dutch breast cancer kindreds. Am J Hum Genet. 1993 Apr;52(4):730–735. [PMC free article] [PubMed] [Google Scholar]
  58. Domagala W., Harezga B., Szadowska A., Markiewski M., Weber K., Osborn M. Nuclear p53 protein accumulates preferentially in medullary and high-grade ductal but rarely in lobular breast carcinomas. Am J Pathol. 1993 Mar;142(3):669–674. [PMC free article] [PubMed] [Google Scholar]
  59. Drebin J. A., Link V. C., Greene M. I. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. Oncogene. 1988 Apr;2(4):387–394. [PubMed] [Google Scholar]
  60. Drebin J. A., Link V. C., Stern D. F., Weinberg R. A., Greene M. I. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell. 1985 Jul;41(3):697–706. doi: 10.1016/s0092-8674(85)80050-7. [DOI] [PubMed] [Google Scholar]
  61. Dunn J. M., Hastrich D. J., Newcomb P., Webb J. C., Maitland N. J., Farndon J. R. Correlation between p53 mutations and antibody staining in breast carcinoma. Br J Surg. 1993 Nov;80(11):1410–1412. doi: 10.1002/bjs.1800801118. [DOI] [PubMed] [Google Scholar]
  62. Elledge R. M., Fuqua S. A., Clark G. M., Pujol P., Allred D. C., McGuire W. L. Prognostic significance of p53 gene alterations in node-negative breast cancer. Breast Cancer Res Treat. 1993;26(3):225–235. doi: 10.1007/BF00665800. [DOI] [PubMed] [Google Scholar]
  63. Engel M., Theisinger B., Seib T., Seitz G., Huwer H., Zang K. D., Welter C., Dooley S. High levels of nm23-H1 and nm23-H2 messenger RNA in human squamous-cell lung carcinoma are associated with poor differentiation and advanced tumor stages. Int J Cancer. 1993 Sep 30;55(3):375–379. doi: 10.1002/ijc.2910550306. [DOI] [PubMed] [Google Scholar]
  64. Finlay C. A. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol. 1993 Jan;13(1):301–306. doi: 10.1128/mcb.13.1.301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Fisher B., Redmond C., Fisher E. R., Caplan R. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol. 1988 Jul;6(7):1076–1087. doi: 10.1200/JCO.1988.6.7.1076. [DOI] [PubMed] [Google Scholar]
  66. Fisher E. R., Sass R., Fisher B. Pathologic findings from the National Surgical Adjuvant Project for Breast Cancers (protocol no. 4). X. Discriminants for tenth year treatment failure. Cancer. 1984 Feb 1;53(3 Suppl):712–723. doi: 10.1002/1097-0142(19840201)53:3+<712::aid-cncr2820531320>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  67. Flejter W. L., Barcroft C. L., Guo S. W., Lynch E. D., Boehnke M., Chandrasekharappa S., Hayes S., Collins F. S., Weber B. L., Glover T. W. Multicolor FISH mapping with Alu-PCR-amplified YAC clone DNA determines the order of markers in the BRCA1 region on chromosome 17q12-q21. Genomics. 1993 Sep;17(3):624–631. doi: 10.1006/geno.1993.1382. [DOI] [PubMed] [Google Scholar]
  68. Foekens J. A., Rio M. C., Seguin P., van Putten W. L., Fauque J., Nap M., Klijn J. G., Chambon P. Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res. 1990 Jul 1;50(13):3832–3837. [PubMed] [Google Scholar]
  69. Foekens J. A., van Putten W. L., Portengen H., Rodenburg C. J., Reubi J. C., Berns P. M., Henzen-Logmans S. C., van der Burg M. E., Alexieva-Figusch J., Klijn J. G. Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-R), insulin-like growth factor-1 (IGF-1-R) and somatostatin (SS-R) in patients with breast and ovarian cancer. J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):815–821. doi: 10.1016/0960-0760(90)90425-k. [DOI] [PubMed] [Google Scholar]
  70. Folkman J. Angiogenesis and breast cancer. J Clin Oncol. 1994 Mar;12(3):441–443. doi: 10.1200/JCO.1994.12.3.441. [DOI] [PubMed] [Google Scholar]
  71. Freeman J. W., Busch R. K., Gyorkey F., Gyorkey P., Ross B. E., Busch H. Identification and characterization of a human proliferation-associated nucleolar antigen with a molecular weight of 120,000 expressed in early G1 phase. Cancer Res. 1988 Mar 1;48(5):1244–1251. [PubMed] [Google Scholar]
  72. Freeman J. W., McGrath P., Bondada V., Selliah N., Ownby H., Maloney T., Busch R. K., Busch H. Prognostic significance of proliferation associated nucleolar antigen P120 in human breast carcinoma. Cancer Res. 1991 Apr 15;51(8):1973–1978. [PubMed] [Google Scholar]
  73. Friend S. H., Dryja T. P., Weinberg R. A. Oncogenes and tumor-suppressing genes. N Engl J Med. 1988 Mar 10;318(10):618–622. doi: 10.1056/NEJM198803103181007. [DOI] [PubMed] [Google Scholar]
  74. Fuller P. J. The steroid receptor superfamily: mechanisms of diversity. FASEB J. 1991 Dec;5(15):3092–3099. doi: 10.1096/fasebj.5.15.1743440. [DOI] [PubMed] [Google Scholar]
  75. Fung Y. K., T'Ang A. The role of the retinoblastoma gene in breast cancer development. Cancer Treat Res. 1992;61:59–68. doi: 10.1007/978-1-4615-3500-3_4. [DOI] [PubMed] [Google Scholar]
  76. Gannon J. V., Greaves R., Iggo R., Lane D. P. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J. 1990 May;9(5):1595–1602. doi: 10.1002/j.1460-2075.1990.tb08279.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Garcia R. L., Coltrera M. D., Gown A. M. Analysis of proliferative grade using anti-PCNA/cyclin monoclonal antibodies in fixed, embedded tissues. Comparison with flow cytometric analysis. Am J Pathol. 1989 Apr;134(4):733–739. [PMC free article] [PubMed] [Google Scholar]
  78. Gasparini G., Gullick W. J., Maluta S., Dalla Palma P., Caffo O., Leonardi E., Boracchi P., Pozza F., Lemoine N. R., Bevilacqua P. c-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma--an immunocytochemical study. Eur J Cancer. 1994;30A(1):16–22. doi: 10.1016/s0959-8049(05)80010-3. [DOI] [PubMed] [Google Scholar]
  79. Gerdes J., Lemke H., Baisch H., Wacker H. H., Schwab U., Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984 Oct;133(4):1710–1715. [PubMed] [Google Scholar]
  80. Glick J. H., Gelber R. D., Goldhirsch A., Senn H. J. Meeting highlights: adjuvant therapy for primary breast cancer. J Natl Cancer Inst. 1992 Oct 7;84(19):1479–1485. doi: 10.1093/jnci/84.19.1479. [DOI] [PubMed] [Google Scholar]
  81. Gramlich T. L., Cohen C., Fritsch C., DeRose P. B., Gansler T. Evaluation of c-erbB-2 amplification in breast carcinoma by differential polymerase chain reaction. Am J Clin Pathol. 1994 Apr;101(4):493–499. doi: 10.1093/ajcp/101.4.493. [DOI] [PubMed] [Google Scholar]
  82. Grigioni W. F., Garbisa S., D'Errico A., Baccarini P., Stetler-Stevenson W. G., Liotta L. A., Mancini A. M. Evaluation of hepatocellular carcinoma aggressiveness by a panel of extracellular matrix antigens. Am J Pathol. 1991 Mar;138(3):647–654. [PMC free article] [PubMed] [Google Scholar]
  83. Gullick W. J., Love S. B., Wright C., Barnes D. M., Gusterson B., Harris A. L., Altman D. G. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer. 1991 Mar;63(3):434–438. doi: 10.1038/bjc.1991.100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Gusterson B. A., Gelber R. D., Goldhirsch A., Price K. N., Säve-Söderborgh J., Anbazhagan R., Styles J., Rudenstam C. M., Golouh R., Reed R. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol. 1992 Jul;10(7):1049–1056. doi: 10.1200/JCO.1992.10.7.1049. [DOI] [PubMed] [Google Scholar]
  85. Hall J. M., Friedman L., Guenther C., Lee M. K., Weber J. L., Black D. M., King M. C. Closing in on a breast cancer gene on chromosome 17q. Am J Hum Genet. 1992 Jun;50(6):1235–1242. [PMC free article] [PubMed] [Google Scholar]
  86. Hall J. M., Lee M. K., Newman B., Morrow J. E., Anderson L. A., Huey B., King M. C. Linkage of early-onset familial breast cancer to chromosome 17q21. Science. 1990 Dec 21;250(4988):1684–1689. doi: 10.1126/science.2270482. [DOI] [PubMed] [Google Scholar]
  87. Hall J. M., Lee M. K., Newman B., Morrow J. E., Anderson L. A., Huey B., King M. C. Linkage of early-onset familial breast cancer to chromosome 17q21. Science. 1990 Dec 21;250(4988):1684–1689. doi: 10.1126/science.2270482. [DOI] [PubMed] [Google Scholar]
  88. Hanzal E., Gitsch G., Kohlberger P., Dadak C., Miechowiecka N., Breitenecker G. Immunohistochemical detection of mutant p53-suppressor gene product in patients with breast cancer: influence on metastasis-free survival. Anticancer Res. 1992 Nov-Dec;12(6B):2325–2329. [PubMed] [Google Scholar]
  89. Harris A. L., Nicholson S. Epidermal growth factor receptors in human breast cancer. Cancer Treat Res. 1988;40:93–118. doi: 10.1007/978-1-4613-1733-3_5. [DOI] [PubMed] [Google Scholar]
  90. Harris A. L. p53 expression in human breast cancer. Adv Cancer Res. 1992;59:69–88. doi: 10.1016/s0065-230x(08)60303-6. [DOI] [PubMed] [Google Scholar]
  91. Harris C. C., Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med. 1993 Oct 28;329(18):1318–1327. doi: 10.1056/NEJM199310283291807. [DOI] [PubMed] [Google Scholar]
  92. Hayes D. F. Angiogenesis and breast cancer. Hematol Oncol Clin North Am. 1994 Feb;8(1):51–71. [PubMed] [Google Scholar]
  93. Heck M. M., Earnshaw W. C. Topoisomerase II: A specific marker for cell proliferation. J Cell Biol. 1986 Dec;103(6 Pt 2):2569–2581. doi: 10.1083/jcb.103.6.2569. [DOI] [PMC free article] [PubMed] [Google Scholar]
  94. Hedley D. W., Rugg C. A., Gelber R. D. Association of DNA index and S-phase fraction with prognosis of nodes positive early breast cancer. Cancer Res. 1987 Sep 1;47(17):4729–4735. [PubMed] [Google Scholar]
  95. Heintz N. H., Leslie K. O., Rogers L. A., Howard P. L. Amplification of the c-erb B-2 oncogene and prognosis of breast adenocarcinoma. Arch Pathol Lab Med. 1990 Feb;114(2):160–163. [PubMed] [Google Scholar]
  96. Hennessy C., Henry J. A., May F. E., Westley B. R., Angus B., Lennard T. W. Expression of the antimetastatic gene nm23 in human breast cancer: an association with good prognosis. J Natl Cancer Inst. 1991 Feb 20;83(4):281–285. doi: 10.1093/jnci/83.4.281. [DOI] [PubMed] [Google Scholar]
  97. Hirayama R., Sawai S., Takagi Y., Mishima Y., Kimura N., Shimada N., Esaki Y., Kurashima C., Utsuyama M., Hirokawa K. Positive relationship between expression of anti-metastatic factor (nm23 gene product or nucleoside diphosphate kinase) and good prognosis in human breast cancer. J Natl Cancer Inst. 1991 Sep 4;83(17):1249–1250. doi: 10.1093/jnci/83.17.1249. [DOI] [PubMed] [Google Scholar]
  98. Hollstein M., Sidransky D., Vogelstein B., Harris C. C. p53 mutations in human cancers. Science. 1991 Jul 5;253(5015):49–53. doi: 10.1126/science.1905840. [DOI] [PubMed] [Google Scholar]
  99. Horak E. R., Leek R., Klenk N., LeJeune S., Smith K., Stuart N., Greenall M., Stepniewska K., Harris A. L. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet. 1992 Nov 7;340(8828):1120–1124. doi: 10.1016/0140-6736(92)93150-l. [DOI] [PubMed] [Google Scholar]
  100. Hori A., Sasada R., Matsutani E., Naito K., Sakura Y., Fujita T., Kozai Y. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res. 1991 Nov 15;51(22):6180–6184. [PubMed] [Google Scholar]
  101. Horiguchi J., Iino Y., Takei H., Yokoe T., Ishida T., Morishita Y. Immunohistochemical study on the expression of c-erbB-2 oncoprotein in breast cancer. Oncology. 1994 Jan-Feb;51(1):47–51. doi: 10.1159/000227309. [DOI] [PubMed] [Google Scholar]
  102. Hupp T. R., Meek D. W., Midgley C. A., Lane D. P. Regulation of the specific DNA binding function of p53. Cell. 1992 Nov 27;71(5):875–886. doi: 10.1016/0092-8674(92)90562-q. [DOI] [PubMed] [Google Scholar]
  103. Hähnel R., Woodings T., Vivian A. B. Prognostic value of estrogen receptors in primary breast cancer. Cancer. 1979 Aug;44(2):671–675. doi: 10.1002/1097-0142(197908)44:2<671::aid-cncr2820440238>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  104. Iglehart J. D., Kraus M. H., Langton B. C., Huper G., Kerns B. J., Marks J. R. Increased erbB-2 gene copies and expression in multiple stages of breast cancer. Cancer Res. 1990 Oct 15;50(20):6701–6707. [PubMed] [Google Scholar]
  105. Ingber D., Fujita T., Kishimoto S., Sudo K., Kanamaru T., Brem H., Folkman J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature. 1990 Dec 6;348(6301):555–557. doi: 10.1038/348555a0. [DOI] [PubMed] [Google Scholar]
  106. Isola J., Visakorpi T., Holli K., Kallioniemi O. P. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst. 1992 Jul 15;84(14):1109–1114. doi: 10.1093/jnci/84.14.1109. [DOI] [PubMed] [Google Scholar]
  107. Jolly K. W., Malkin D., Douglass E. C., Brown T. F., Sinclair A. E., Look A. T. Splice-site mutation of the p53 gene in a family with hereditary breast-ovarian cancer. Oncogene. 1994 Jan;9(1):97–102. [PubMed] [Google Scholar]
  108. Jänicke F., Schmitt M., Graeff H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost. 1991 Jul;17(3):303–312. doi: 10.1055/s-2007-1002624. [DOI] [PubMed] [Google Scholar]
  109. Kallioniemi O. P., Holli K., Visakorpi T., Koivula T., Helin H. H., Isola J. J. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer. 1991 Nov 11;49(5):650–655. doi: 10.1002/ijc.2910490504. [DOI] [PubMed] [Google Scholar]
  110. Kallioniemi O. P., Kallioniemi A., Kurisu W., Thor A., Chen L. C., Smith H. S., Waldman F. M., Pinkel D., Gray J. W. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5321–5325. doi: 10.1073/pnas.89.12.5321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  111. Kandalaft P. L., Chang K. L., Ahn C. W., Traweek S. T., Mehta P., Battifora H. Prognostic significance of immunohistochemical analysis of cathepsin D in low-stage breast cancer. Cancer. 1993 May 1;71(9):2756–2763. doi: 10.1002/1097-0142(19930501)71:9<2756::aid-cncr2820710912>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  112. Kasid A., Lippman M. E. Estrogen and oncogene mediated growth regulation of human breast cancer cells. J Steroid Biochem. 1987;27(1-3):465–470. doi: 10.1016/0022-4731(87)90341-4. [DOI] [PubMed] [Google Scholar]
  113. Kerns B. J., Jordan P. A., Moore M. B., Humphrey P. A., Berchuck A., Kohler M. F., Bast R. C., Jr, Iglehart J. D., Marks J. R. p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. J Histochem Cytochem. 1992 Jul;40(7):1047–1051. doi: 10.1177/40.7.1607637. [DOI] [PubMed] [Google Scholar]
  114. Klijn J. G., Berns P. M., Schmitz P. I., Foekens J. A. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev. 1992 Feb;13(1):3–17. doi: 10.1210/edrv-13-1-3. [DOI] [PubMed] [Google Scholar]
  115. Knudson A. G. Antioncogenes and human cancer. Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):10914–10921. doi: 10.1073/pnas.90.23.10914. [DOI] [PMC free article] [PubMed] [Google Scholar]
  116. Kobayashi S., Iwase H., Itoh Y., Fukuoka H., Yamashita H., Kuzushima T., Iwata H., Masaoka A., Kimura N. Estrogen receptor, c-erbB-2 and nm23/NDP kinase expression in the intraductal and invasive components of human breast cancers. Jpn J Cancer Res. 1992 Aug;83(8):859–865. doi: 10.1111/j.1349-7006.1992.tb01991.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  117. Koenders P. G., Beex L. V., Kienhuis C. B., Kloppenborg P. W., Benraad T. J. Epidermal growth factor receptor and prognosis in human breast cancer: a prospective study. Breast Cancer Res Treat. 1993;25(1):21–27. doi: 10.1007/BF00662397. [DOI] [PubMed] [Google Scholar]
  118. Kreipe H., Wacker H. H., Heidebrecht H. J., Haas K., Hauberg M., Tiemann M., Parwaresch R. Determination of the growth fraction in non-Hodgkin's lymphomas by monoclonal antibody Ki-S5 directed against a formalin-resistant epitope of the Ki-67 antigen. Am J Pathol. 1993 Jun;142(6):1689–1694. [PMC free article] [PubMed] [Google Scholar]
  119. Kute T. E., Muss H. B., Anderson D., Crumb K., Miller B., Burns D., Dube L. A. Relationship of steroid receptor, cell kinetics, and clinical status in patients with breast cancer. Cancer Res. 1981 Sep;41(9 Pt 1):3524–3529. [PubMed] [Google Scholar]
  120. Lacombe M. L., Sastre-Garau X., Lascu I., Vonica A., Wallet V., Thiery J. P., Véron M. Overexpression of nucleoside diphosphate kinase (Nm23) in solid tumours. Eur J Cancer. 1991;27(10):1302–1307. doi: 10.1016/0277-5379(91)90101-i. [DOI] [PubMed] [Google Scholar]
  121. Lalle P., De Latour M., Rio P., Bignon Y. J. Detection of allelic losses on 17q12-q21 chromosomal region in benign lesions and malignant tumors occurring in a familial context. Oncogene. 1994 Feb;9(2):437–442. [PubMed] [Google Scholar]
  122. Law M. L., Kao F. T., Wei Q., Hartz J. A., Greene G. L., Zarucki-Schulz T., Conneely O. M., Jones C., Puck T. T., O'Malley B. W. The progesterone receptor gene maps to human chromosome band 11q13, the site of the mammary oncogene int-2. Proc Natl Acad Sci U S A. 1987 May;84(9):2877–2881. doi: 10.1073/pnas.84.9.2877. [DOI] [PMC free article] [PubMed] [Google Scholar]
  123. Lee E. Y., To H., Shew J. Y., Bookstein R., Scully P., Lee W. H. Inactivation of the retinoblastoma susceptibility gene in human breast cancers. Science. 1988 Jul 8;241(4862):218–221. doi: 10.1126/science.3388033. [DOI] [PubMed] [Google Scholar]
  124. Leong A. S., Raymond W. A. Prognostic parameters in breast cancer. Pathology. 1989 Jul;21(3):169–175. doi: 10.3109/00313028909061053. [DOI] [PubMed] [Google Scholar]
  125. Levine A. J., Momand J., Finlay C. A. The p53 tumour suppressor gene. Nature. 1991 Jun 6;351(6326):453–456. doi: 10.1038/351453a0. [DOI] [PubMed] [Google Scholar]
  126. Levine A. J. The p53 tumour suppressor gene and product. Cancer Surv. 1992;12:59–79. [PubMed] [Google Scholar]
  127. Lewis S., Locker A., Todd J. H., Bell J. A., Nicholson R., Elston C. W., Blamey R. W., Ellis I. O. Expression of epidermal growth factor receptor in breast carcinoma. J Clin Pathol. 1990 May;43(5):385–389. doi: 10.1136/jcp.43.5.385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  128. Li B. D., Harlow S. P., Budnick R. M., Sheedy D. L., Stewart C. C. Detection of HER-2/neu oncogene amplification in flow cytometry-sorted breast ductal cells by competitive polymerase chain reaction. Cancer. 1994 Jun 1;73(11):2771–2778. doi: 10.1002/1097-0142(19940601)73:11<2771::aid-cncr2820731120>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  129. Li F. P., Fraumeni J. F., Jr Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med. 1969 Oct;71(4):747–752. doi: 10.7326/0003-4819-71-4-747. [DOI] [PubMed] [Google Scholar]
  130. Liotta L. A., Saidel M. G., Kleinerman J. The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Res. 1976 Mar;36(3):889–894. [PubMed] [Google Scholar]
  131. Lipponen H. J., Aaltomaa S., Syrjänen S., Syrjänen K. c-erbB-2 oncogene related to p53 expression, cell proliferation and prognosis in breast cancer. Anticancer Res. 1993 Jul-Aug;13(4):1147–1152. [PubMed] [Google Scholar]
  132. Lipponen P., Aaltomaa S., Eskelinen M., Kosma V. M., Marin S., Syrjänen K. The changing importance of prognostic factors in breast cancer during long-term follow-up. Int J Cancer. 1992 Jul 9;51(5):698–702. doi: 10.1002/ijc.2910510506. [DOI] [PubMed] [Google Scholar]
  133. Lipponen P., Ji H., Aaltomaa S., Syrjänen S., Syrjänen K. p53 protein expression in breast cancer as related to histopathological characteristics and prognosis. Int J Cancer. 1993 Aug 19;55(1):51–56. doi: 10.1002/ijc.2910550110. [DOI] [PubMed] [Google Scholar]
  134. Liu E., Thor A., He M., Barcos M., Ljung B. M., Benz C. The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. Oncogene. 1992 May;7(5):1027–1032. [PubMed] [Google Scholar]
  135. Loda M. Polymerase chain reaction-based methods for the detection of mutations in oncogenes and tumor suppressor genes. Hum Pathol. 1994 Jun;25(6):564–571. doi: 10.1016/0046-8177(94)90220-8. [DOI] [PubMed] [Google Scholar]
  136. Loda M. Polymerase chain reaction-based methods for the detection of mutations in oncogenes and tumor suppressor genes. Hum Pathol. 1994 Jun;25(6):564–571. doi: 10.1016/0046-8177(94)90220-8. [DOI] [PubMed] [Google Scholar]
  137. Lodato R. F., Maguire H. C., Jr, Greene M. I., Weiner D. B., LiVolsi V. A. Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Mod Pathol. 1990 Jul;3(4):449–454. [PubMed] [Google Scholar]
  138. Lovekin C., Ellis I. O., Locker A., Robertson J. F., Bell J., Nicholson R., Gullick W. J., Elston C. W., Blamey R. W. c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer. 1991 Mar;63(3):439–443. doi: 10.1038/bjc.1991.101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  139. Lowe S. W., Ruley H. E., Jacks T., Housman D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993 Sep 24;74(6):957–967. doi: 10.1016/0092-8674(93)90719-7. [DOI] [PubMed] [Google Scholar]
  140. Lupu R., Colomer R., Kannan B., Lippman M. E. Characterization of a growth factor that binds exclusively to the erbB-2 receptor and induces cellular responses. Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2287–2291. doi: 10.1073/pnas.89.6.2287. [DOI] [PMC free article] [PubMed] [Google Scholar]
  141. Lönn U., Lönn S., Nylen U., Stenkvist B. Appearance and detection of multiple copies of the mdr-1 gene in clinical samples of mammary carcinoma. Int J Cancer. 1992 Jul 9;51(5):682–686. doi: 10.1002/ijc.2910510503. [DOI] [PubMed] [Google Scholar]
  142. Macaulay V. M. Insulin-like growth factors and cancer. Br J Cancer. 1992 Mar;65(3):311–320. doi: 10.1038/bjc.1992.65. [DOI] [PMC free article] [PubMed] [Google Scholar]
  143. Maguire H. C., Jr, Hellman M. E., Greene M. I., Yeh I. Expression of c-erbB-2 in in situ and in adjacent invasive ductal adenocarcinomas of the female breast. Pathobiology. 1992;60(3):117–121. doi: 10.1159/000163709. [DOI] [PubMed] [Google Scholar]
  144. Majerus P. W., Ross T. S., Cunningham T. W., Caldwell K. K., Jefferson A. B., Bansal V. S. Recent insights in phosphatidylinositol signaling. Cell. 1990 Nov 2;63(3):459–465. doi: 10.1016/0092-8674(90)90442-h. [DOI] [PubMed] [Google Scholar]
  145. Malkin D., Jolly K. W., Barbier N., Look A. T., Friend S. H., Gebhardt M. C., Andersen T. I., Børresen A. L., Li F. P., Garber J. Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med. 1992 May 14;326(20):1309–1315. doi: 10.1056/NEJM199205143262002. [DOI] [PubMed] [Google Scholar]
  146. Malkin D., Li F. P., Strong L. C., Fraumeni J. F., Jr, Nelson C. E., Kim D. H., Kassel J., Gryka M. A., Bischoff F. Z., Tainsky M. A. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990 Nov 30;250(4985):1233–1238. doi: 10.1126/science.1978757. [DOI] [PubMed] [Google Scholar]
  147. Marchetti A., Buttitta F., Pellegrini S., Campani D., Diella F., Cecchetti D., Callahan R., Bistocchi M. p53 mutations and histological type of invasive breast carcinoma. Cancer Res. 1993 Oct 1;53(19):4665–4669. [PubMed] [Google Scholar]
  148. Marchetti A., Buttitta F., Pellegrini S., Diella F., Campani D., Cecchetti D., Squartini F., Callahan R., Bistocchi M. p53 mutations and histologic type of invasive breast carcinoma. A polymerase chain reaction-single-strand conformation polymorphism and immunohistochemical analysis. Ann N Y Acad Sci. 1993 Nov 30;698:114–119. doi: 10.1111/j.1749-6632.1993.tb17196.x. [DOI] [PubMed] [Google Scholar]
  149. Marks J. R., Humphrey P. A., Wu K., Berry D., Bandarenko N., Kerns B. J., Iglehart J. D. Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. Ann Surg. 1994 Apr;219(4):332–341. doi: 10.1097/00000658-199404000-00002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  150. Marks J. R., Humphrey P. A., Wu K., Berry D., Bandarenko N., Kerns B. J., Iglehart J. D. Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. Ann Surg. 1994 Apr;219(4):332–341. doi: 10.1097/00000658-199404000-00002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  151. Marques L. A., Franco E. L., Torloni H., Brentani M. M., da Silva-Neto J. B., Brentani R. R. Independent prognostic value of laminin receptor expression in breast cancer survival. Cancer Res. 1990 Mar 1;50(5):1479–1483. [PubMed] [Google Scholar]
  152. Marsigliante S., Biscozzo L., Greco S., Leo G., Storelli C. Relation of cathepsin D level to the estrogen receptor in human breast cancer. Int J Clin Lab Res. 1992;22(1):52–57. doi: 10.1007/BF02591395. [DOI] [PubMed] [Google Scholar]
  153. Martinazzi M., Crivelli F., Zampatti C., Martinazzi S. Relationship between p53 expression and other prognostic factors in human breast carcinoma. An immunohistochemical study. Am J Clin Pathol. 1993 Sep;100(3):213–217. doi: 10.1093/ajcp/100.3.213. [DOI] [PubMed] [Google Scholar]
  154. Martinazzi M., Crivelli F., Zampatti C., Pisani P. Low, intermediate and high grade breast carcinomas as determined by histotyping, immunohistochemical prognosticators and histological grading. Pathologica. 1992 Jan-Feb;84(1089):33–47. [PubMed] [Google Scholar]
  155. Marx D., Schauer A., Reiche C., May A., Ummenhofer L., Reles A., Rauschecker H., Sauer R., Schumacher M. c-erbB2 expression in correlation to other biological parameters of breast cancer. J Cancer Res Clin Oncol. 1990;116(1):15–20. doi: 10.1007/BF01612634. [DOI] [PubMed] [Google Scholar]
  156. Mason B. H., Holdaway I. M., Mullins P. R., Yee L. H., Kay R. G. Progesterone and estrogen receptors as prognostic variables in breast cancer. Cancer Res. 1983 Jun;43(6):2985–2990. [PubMed] [Google Scholar]
  157. Matsui Y., Halter S. A., Holt J. T., Hogan B. L., Coffey R. J. Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice. Cell. 1990 Jun 15;61(6):1147–1155. doi: 10.1016/0092-8674(90)90077-r. [DOI] [PubMed] [Google Scholar]
  158. Mazars R., Spinardi L., BenCheikh M., Simony-Lafontaine J., Jeanteur P., Theillet C. p53 mutations occur in aggressive breast cancer. Cancer Res. 1992 Jul 15;52(14):3918–3923. [PubMed] [Google Scholar]
  159. McCarty K. S., Jr, Barton T. K., Fetter B. F., Woodard B. H., Mossler J. A., Reeves W., Daly J., Wilkinson W. E., McCarty K. S., Sr Correlation of estrogen and progesterone receptors with histologic differentiation in mammary carcinoma. Cancer. 1980 Dec 15;46(12 Suppl):2851–2858. doi: 10.1002/1097-0142(19801215)46:12+<2851::aid-cncr2820461424>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  160. McGuire W. L. Breast cancer prognostic factors: evaluation guidelines. J Natl Cancer Inst. 1991 Feb 6;83(3):154–155. doi: 10.1093/jnci/83.3.154. [DOI] [PubMed] [Google Scholar]
  161. McGuire W. L., Clark G. M. Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med. 1992 Jun 25;326(26):1756–1761. doi: 10.1056/NEJM199206253262607. [DOI] [PubMed] [Google Scholar]
  162. Merlo G. R., Bernardi A., Diella F., Venesio T., Cappa A. P., Callahan R., Liscia D. S. In primary human breast carcinomas mutations in exons 5 and 6 of the p53 gene are associated with a high S-phase index. Int J Cancer. 1993 Jun 19;54(4):531–535. doi: 10.1002/ijc.2910540402. [DOI] [PubMed] [Google Scholar]
  163. Meyer J. S., Province M. Proliferative index of breast carcinoma by thymidine labeling: prognostic power independent of stage, estrogen and progesterone receptors. Breast Cancer Res Treat. 1988 Oct;12(2):191–204. doi: 10.1007/BF01805940. [DOI] [PubMed] [Google Scholar]
  164. Mohammed R. H., Lakatua D. J., Haus E., Yasmineh W. J. Estrogen and progesterone receptors in human breast cancer. Correlation with histologic subtype and degree of differentiation. Cancer. 1986 Sep 1;58(5):1076–1081. doi: 10.1002/1097-0142(19860901)58:5<1076::aid-cncr2820580516>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  165. Moll U. M., Riou G., Levine A. J. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7262–7266. doi: 10.1073/pnas.89.15.7262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  166. Momand J., Zambetti G. P., Olson D. C., George D., Levine A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992 Jun 26;69(7):1237–1245. doi: 10.1016/0092-8674(92)90644-r. [DOI] [PubMed] [Google Scholar]
  167. Montcourrier P., Mangeat P. H., Salazar G., Morisset M., Sahuquet A., Rochefort H. Cathepsin D in breast cancer cells can digest extracellular matrix in large acidic vesicles. Cancer Res. 1990 Sep 15;50(18):6045–6054. [PubMed] [Google Scholar]
  168. Monteagudo C., Merino M. J., San-Juan J., Liotta L. A., Stetler-Stevenson W. G. Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue. Am J Pathol. 1990 Mar;136(3):585–592. [PMC free article] [PubMed] [Google Scholar]
  169. Mourad W. A., Erkman-Balis B., Livingston S., Shoukri M., Cox C. E., Nicosia S. V., Rowlands D. T., Jr Argyrophilic nucleolar organizer regions in breast carcinoma. Correlation with DNA flow cytometry, histopathology, and lymph node status. Cancer. 1992 Apr 1;69(7):1739–1744. doi: 10.1002/1097-0142(19920401)69:7<1739::aid-cncr2820690715>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  170. Muss H. B., Thor A. D., Berry D. A., Kute T., Liu E. T., Koerner F., Cirrincione C. T., Budman D. R., Wood W. C., Barcos M. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994 May 5;330(18):1260–1266. doi: 10.1056/NEJM199405053301802. [DOI] [PubMed] [Google Scholar]
  171. Naber S. P., Tsutsumi Y., Yin S., Zolnay S. A., Mobtaker H., Marks P. J., McKenzie S. J., DeLellis R. A., Wolfe H. J. Strategies for the analysis of oncogene overexpression. Studies of the neu oncogene in breast carcinoma. Am J Clin Pathol. 1990 Aug;94(2):125–136. doi: 10.1093/ajcp/94.2.125. [DOI] [PubMed] [Google Scholar]
  172. Nagy J. A., Brown L. F., Senger D. R., Lanir N., Van de Water L., Dvorak A. M., Dvorak H. F. Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochim Biophys Acta. 1989 Feb;948(3):305–326. doi: 10.1016/0304-419x(89)90004-8. [DOI] [PubMed] [Google Scholar]
  173. Narod S. A., Feunteun J., Lynch H. T., Watson P., Conway T., Lynch J., Lenoir G. M. Familial breast-ovarian cancer locus on chromosome 17q12-q23. Lancet. 1991 Jul 13;338(8759):82–83. doi: 10.1016/0140-6736(91)90076-2. [DOI] [PubMed] [Google Scholar]
  174. Narod S. A., Feunteun J., Lynch H. T., Watson P., Conway T., Lynch J., Lenoir G. M. Familial breast-ovarian cancer locus on chromosome 17q12-q23. Lancet. 1991 Jul 13;338(8759):82–83. doi: 10.1016/0140-6736(91)90076-2. [DOI] [PubMed] [Google Scholar]
  175. Negrini M., Sabbioni S., Haldar S., Possati L., Castagnoli A., Corallini A., Barbanti-Brodano G., Croce C. M. Tumor and growth suppression of breast cancer cells by chromosome 17-associated functions. Cancer Res. 1994 Apr 1;54(7):1818–1824. [PubMed] [Google Scholar]
  176. Nicholson R. I., McClelland R. A., Finlay P., Eaton C. L., Gullick W. J., Dixon A. R., Robertson J. F., Ellis I. O., Blamey R. W. Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer. 1993;29A(7):1018–1023. doi: 10.1016/s0959-8049(05)80215-1. [DOI] [PubMed] [Google Scholar]
  177. O'Reilly S. M., Barnes D. M., Camplejohn R. S., Bartkova J., Gregory W. M., Richards M. A. The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. Br J Cancer. 1991 Mar;63(3):444–446. doi: 10.1038/bjc.1991.102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  178. O'Reilly S. M., Camplejohn R. S., Barnes D. M., Millis R. R., Allen D., Rubens R. D., Richards M. A. DNA index, S-phase fraction, histological grade and prognosis in breast cancer. Br J Cancer. 1990 May;61(5):671–674. doi: 10.1038/bjc.1990.152. [DOI] [PMC free article] [PubMed] [Google Scholar]
  179. O'Reilly S. M., Richards M. A. Is DNA flow cytometry a useful investigation in breast cancer? Eur J Cancer. 1992;28(2-3):504–507. doi: 10.1016/s0959-8049(05)80088-7. [DOI] [PubMed] [Google Scholar]
  180. Oliner J. D., Pietenpol J. A., Thiagalingam S., Gyuris J., Kinzler K. W., Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature. 1993 Apr 29;362(6423):857–860. doi: 10.1038/362857a0. [DOI] [PubMed] [Google Scholar]
  181. Osaki A., Toi M., Yamada H., Kawami H., Kuroi K., Toge T. Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients. Am J Surg. 1992 Oct;164(4):323–326. doi: 10.1016/s0002-9610(05)80897-9. [DOI] [PubMed] [Google Scholar]
  182. Osborne C. K., Yochmowitz M. G., Knight W. A., 3rd, McGuire W. L. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer. 1980 Dec 15;46(12 Suppl):2884–2888. doi: 10.1002/1097-0142(19801215)46:12+<2884::aid-cncr2820461429>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  183. Ottestad L., Andersen T. I., Nesland J. M., Skrede M., Tveit K. M., Nustad K., Børresen A. L. Amplification of c-erbB-2, int-2 and c-myc genes in node-negative breast carcinomas. Relationship to prognosis. Acta Oncol. 1993;32(3):289–294. doi: 10.3109/02841869309093597. [DOI] [PubMed] [Google Scholar]
  184. Paik S., Hazan R., Fisher E. R., Sass R. E., Fisher B., Redmond C., Schlessinger J., Lippman M. E., King C. R. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol. 1990 Jan;8(1):103–112. doi: 10.1200/JCO.1990.8.1.103. [DOI] [PubMed] [Google Scholar]
  185. Papa V., Pezzino V., Costantino A., Belfiore A., Giuffrida D., Frittitta L., Vannelli G. B., Brand R., Goldfine I. D., Vigneri R. Elevated insulin receptor content in human breast cancer. J Clin Invest. 1990 Nov;86(5):1503–1510. doi: 10.1172/JCI114868. [DOI] [PMC free article] [PubMed] [Google Scholar]
  186. Paterson M. C., Dietrich K. D., Danyluk J., Paterson A. H., Lees A. W., Jamil N., Hanson J., Jenkins H., Krause B. E., McBlain W. A. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res. 1991 Jan 15;51(2):556–567. [PubMed] [Google Scholar]
  187. Peles E., Bacus S. S., Koski R. A., Lu H. S., Wen D., Ogden S. G., Levy R. B., Yarden Y. Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell. 1992 Apr 3;69(1):205–216. doi: 10.1016/0092-8674(92)90131-u. [DOI] [PubMed] [Google Scholar]
  188. Peyrat J. P., Bonneterre J., Vennin P. H., Jammes H., Beuscart R., Hecquet B., Djiane J., Lefebvre J., Demaille A. Insulin-like growth factor 1 receptors (IGF1-R) and IGF1 in human breast tumors. J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):823–827. doi: 10.1016/0960-0760(90)90426-l. [DOI] [PubMed] [Google Scholar]
  189. Picard D., Kumar V., Chambon P., Yamamoto K. R. Signal transduction by steroid hormones: nuclear localization is differentially regulated in estrogen and glucocorticoid receptors. Cell Regul. 1990 Feb;1(3):291–299. doi: 10.1091/mbc.1.3.291. [DOI] [PMC free article] [PubMed] [Google Scholar]
  190. Pignatelli M., Cardillo M. R., Hanby A., Stamp G. W. Integrins and their accessory adhesion molecules in mammary carcinomas: loss of polarization in poorly differentiated tumors. Hum Pathol. 1992 Oct;23(10):1159–1166. doi: 10.1016/0046-8177(92)90034-z. [DOI] [PubMed] [Google Scholar]
  191. Poller D. N., Hutchings C. E., Galea M., Bell J. A., Nicholson R. A., Elston C. W., Blamey R. W., Ellis I. O. p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor. Br J Cancer. 1992 Sep;66(3):583–588. doi: 10.1038/bjc.1992.318. [DOI] [PMC free article] [PubMed] [Google Scholar]
  192. Poller D. N., Roberts E. C., Bell J. A., Elston C. W., Blamey R. W., Ellis I. O. p53 protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein. Hum Pathol. 1993 May;24(5):463–468. doi: 10.1016/0046-8177(93)90157-c. [DOI] [PubMed] [Google Scholar]
  193. Ponglikitmongkol M., Green S., Chambon P. Genomic organization of the human oestrogen receptor gene. EMBO J. 1988 Nov;7(11):3385–3388. doi: 10.1002/j.1460-2075.1988.tb03211.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  194. Porter P. L., Garcia R., Moe R., Corwin D. J., Gown A. M. C-erbB-2 oncogene protein in in situ and invasive lobular breast neoplasia. Cancer. 1991 Jul 15;68(2):331–334. doi: 10.1002/1097-0142(19910715)68:2<331::aid-cncr2820680221>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  195. Predine J., Spyratos F., Prud'homme J. F., Andrieu C., Hacene K., Brunet M., Pallud C., Milgrom E. Enzyme-linked immunosorbent assay of pS2 in breast cancers, benign tumors, and normal breast tissues. Correlation with prognosis and adjuvant hormone therapy. Cancer. 1992 Apr 15;69(8):2116–2123. doi: 10.1002/1097-0142(19920415)69:8<2116::aid-cncr2820690818>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  196. Press M. F., Hung G., Godolphin W., Slamon D. J. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res. 1994 May 15;54(10):2771–2777. [PubMed] [Google Scholar]
  197. Press M. F., Pike M. C., Chazin V. R., Hung G., Udove J. A., Markowicz M., Danyluk J., Godolphin W., Sliwkowski M., Akita R. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res. 1993 Oct 15;53(20):4960–4970. [PubMed] [Google Scholar]
  198. Pyke C., Ralfkiaer E., Huhtala P., Hurskainen T., Danø K., Tryggvason K. Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization. Cancer Res. 1992 Mar 1;52(5):1336–1341. [PubMed] [Google Scholar]
  199. Raemaekers J. M., Beex L. V., Koenders A. J., Pieters G. F., Smals A. G., Benraad T. J., Kloppenborg P. W. Disease-free interval and estrogen receptor activity in tumor tissue of patients with primary breast cancer: analysis after long-term follow-up. Breast Cancer Res Treat. 1985;6(2):123–130. doi: 10.1007/BF02235743. [DOI] [PubMed] [Google Scholar]
  200. Ramachandra S., Machin L., Ashley S., Monaghan P., Gusterson B. A. Immunohistochemical distribution of c-erbB-2 in in situ breast carcinoma--a detailed morphological analysis. J Pathol. 1990 May;161(1):7–14. doi: 10.1002/path.1711610104. [DOI] [PubMed] [Google Scholar]
  201. Raymond W. A., Leong A. S. Nucleolar organizer regions relate to growth fractions in human breast carcinoma. Hum Pathol. 1989 Aug;20(8):741–746. doi: 10.1016/0046-8177(89)90066-x. [DOI] [PubMed] [Google Scholar]
  202. Raymond W. A., Leong A. S. The relationship between growth fractions and oestrogen receptors in human breast carcinoma, as determined by immunohistochemical staining. J Pathol. 1989 Jul;158(3):203–211. doi: 10.1002/path.1711580306. [DOI] [PubMed] [Google Scholar]
  203. Remvikos Y., Beuzeboc P., Zajdela A., Voillemot N., Magdelénat H., Pouillart P. Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J Natl Cancer Inst. 1989 Sep 20;81(18):1383–1387. doi: 10.1093/jnci/81.18.1383. [DOI] [PubMed] [Google Scholar]
  204. Richner J., Gerber H. A., Locher G. W., Goldhirsch A., Gelber R. D., Gullick W. J., Berger M. S., Groner B., Hynes N. E. c-erbB-2 protein expression in node negative breast cancer. Ann Oncol. 1990 Jul;1(4):263–268. doi: 10.1093/oxfordjournals.annonc.a057745. [DOI] [PubMed] [Google Scholar]
  205. Rilke F., Colnaghi M. I., Cascinelli N., Andreola S., Baldini M. T., Bufalino R., Della Porta G., Ménard S., Pierotti M. A., Testori A. Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer. 1991 Aug 19;49(1):44–49. doi: 10.1002/ijc.2910490109. [DOI] [PubMed] [Google Scholar]
  206. Riou G., Lê M. G., Travagli J. P., Levine A. J., Moll U. M. Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast carcinoma. J Natl Cancer Inst. 1993 Nov 3;85(21):1765–1767. doi: 10.1093/jnci/85.21.1765. [DOI] [PubMed] [Google Scholar]
  207. Ro J. S., el-Naggar A., Ro J. Y., Blick M., Frye D., Fraschini G., Fritsche H., Hortobagyi G. c-erbB-2 amplification in node-negative human breast cancer. Cancer Res. 1989 Dec 15;49(24 Pt 1):6941–6944. [PubMed] [Google Scholar]
  208. Ro J., North S. M., Gallick G. E., Hortobagyi G. N., Gutterman J. U., Blick M. Amplified and overexpressed epidermal growth factor receptor gene in uncultured primary human breast carcinoma. Cancer Res. 1988 Jan 1;48(1):161–164. [PubMed] [Google Scholar]
  209. Rosenberg S., Stracher A., Lucas R. C. Isolation and characterization of actin and actin-binding protein from human platelets. J Cell Biol. 1981 Oct;91(1):201–211. doi: 10.1083/jcb.91.1.201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  210. Royds J. A., Stephenson T. J., Rees R. C., Shorthouse A. J., Silcocks P. B. Nm23 protein expression in ductal in situ and invasive human breast carcinoma. J Natl Cancer Inst. 1993 May 5;85(9):727–731. doi: 10.1093/jnci/85.9.727. [DOI] [PubMed] [Google Scholar]
  211. Ríos M. A., Macías A., Pérez R., Lage A., Skoog L. Receptors for epidermal growth factor and estrogen as predictors of relapse in patients with mammary carcinoma. Anticancer Res. 1988 Jan-Feb;8(1):173–176. [PubMed] [Google Scholar]
  212. Sacks N. P., Smith K., Norman A. P., Greenall M., LeJeune S., Harris A. L. Cathepsin D levels in primary breast cancers: relationship with epidermal growth factor receptor, oestrogen receptor and axillary nodal status. Eur J Cancer. 1993;29A(3):426–428. doi: 10.1016/0959-8049(93)90401-z. [DOI] [PubMed] [Google Scholar]
  213. Sahin A. A., Ro J., Ro J. Y., Blick M. B., el-Naggar A. K., Ordonez N. G., Fritsche H. A., Smith T. L., Hortobagyi G. N., Ayala A. G. Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis. Cancer. 1991 Aug 1;68(3):549–557. doi: 10.1002/1097-0142(19910801)68:3<549::aid-cncr2820680318>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  214. Sainsbury J. R., Farndon J. R., Needham G. K., Malcolm A. J., Harris A. L. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet. 1987 Jun 20;1(8547):1398–1402. doi: 10.1016/s0140-6736(87)90593-9. [DOI] [PubMed] [Google Scholar]
  215. Sarkar F. H., Smith M. R., Hoover T., Princler G., Crissman J. D., Visscher D. W., Longo D. L., Kung H. F., Raziuddin c-erbB-2 promoter-specific DNA-binding protein isolated from human breast cancer tissues displays mitogenic activity. J Biol Chem. 1994 Apr 22;269(16):12285–12289. [PubMed] [Google Scholar]
  216. Sastre-Garau X., Lacombe M. L., Jouve M., Véron M., Magdelénat H. Nucleoside diphosphate kinase/NM23 expression in breast cancer: lack of correlation with lymph-node metastasis. Int J Cancer. 1992 Feb 20;50(4):533–538. doi: 10.1002/ijc.2910500406. [DOI] [PubMed] [Google Scholar]
  217. Sawan A., Randall B., Angus B., Wright C., Henry J. A., Ostrowski J., Hennessy C., Lennard T. W., Corbett I., Horne C. H. Retinoblastoma and p53 gene expression related to relapse and survival in human breast cancer: an immunohistochemical study. J Pathol. 1992 Sep;168(1):23–28. doi: 10.1002/path.1711680105. [DOI] [PubMed] [Google Scholar]
  218. Schimmelpenning H., Eriksson E. T., Falkmer U. G., Rutqvist L. E., Johansson H., Fallenius A., Auer G. U. Prognostic significance of immunohistochemical c-erbB-2 proto-oncogene expression and nuclear DNA content in human breast cancer. Eur J Surg Oncol. 1992 Dec;18(6):530–537. [PubMed] [Google Scholar]
  219. Schmitt M., Jänicke F., Graeff H. Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer. Blood Coagul Fibrinolysis. 1990 Dec;1(6):695–702. [PubMed] [Google Scholar]
  220. Schwabe J. W., Neuhaus D., Rhodes D. Solution structure of the DNA-binding domain of the oestrogen receptor. Nature. 1990 Nov 29;348(6300):458–461. doi: 10.1038/348458a0. [DOI] [PubMed] [Google Scholar]
  221. Sestini R., Orlando C., Zentilin L., Gelmini S., Pinzani P., Bianchi S., Selli C., Giacca M., Pazzagli M. Measuring c-erbB-2 oncogene amplification in fresh and paraffin-embedded tumors by competitive polymerase chain reaction. Clin Chem. 1994 Apr;40(4):630–636. [PubMed] [Google Scholar]
  222. Sigurdsson H., Baldetorp B., Borg A., Dalberg M., Fernö M., Killander D., Olsson H. Indicators of prognosis in node-negative breast cancer. N Engl J Med. 1990 Apr 12;322(15):1045–1053. doi: 10.1056/NEJM199004123221505. [DOI] [PubMed] [Google Scholar]
  223. Silverstrini R., Daidone M. G., Di Fronzo G. Relationship between proliferative activity and estrogen receptors in breast cancer. Cancer. 1979 Aug;44(2):665–670. doi: 10.1002/1097-0142(197908)44:2<665::aid-cncr2820440237>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  224. Silvestrini R., Benini E., Daidone M. G., Veneroni S., Boracchi P., Cappelletti V., Di Fronzo G., Veronesi U. p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst. 1993 Jun 16;85(12):965–970. doi: 10.1093/jnci/85.12.965. [DOI] [PubMed] [Google Scholar]
  225. Silvestrini R., Daidone M. G., Di Fronzo G., Morabito A., Valagussa P., Bonadonna G. Prognostic implication of labeling index versus estrogen receptors and tumor size in node-negative breast cancer. Breast Cancer Res Treat. 1986;7(3):161–169. doi: 10.1007/BF01806246. [DOI] [PubMed] [Google Scholar]
  226. Simpson J. F., O'Malley F., Dupont W. D., Page D. L. Heterogeneous expression of nm23 gene product in noninvasive breast carcinoma. Cancer. 1994 May 1;73(9):2352–2358. doi: 10.1002/1097-0142(19940501)73:9<2352::aid-cncr2820730918>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  227. Slamon D. J., Clark G. M., Wong S. G., Levin W. J., Ullrich A., McGuire W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987 Jan 9;235(4785):177–182. doi: 10.1126/science.3798106. [DOI] [PubMed] [Google Scholar]
  228. Slamon D. J., Clark G. M., Wong S. G., Levin W. J., Ullrich A., McGuire W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987 Jan 9;235(4785):177–182. doi: 10.1126/science.3798106. [DOI] [PubMed] [Google Scholar]
  229. Slamon D. J., Godolphin W., Jones L. A., Holt J. A., Wong S. G., Keith D. E., Levin W. J., Stuart S. G., Udove J., Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989 May 12;244(4905):707–712. doi: 10.1126/science.2470152. [DOI] [PubMed] [Google Scholar]
  230. Smith K. L., Robbins P. D., Dawkins H. J., Papadimitriou J. M., Redmond S. L., Carrello S., Harvey J. M., Sterrett G. F. c-erbB-2 amplification in breast cancer: detection in formalin-fixed, paraffin-embedded tissue by in situ hybridization. Hum Pathol. 1994 Apr;25(4):413–418. doi: 10.1016/0046-8177(94)90152-x. [DOI] [PubMed] [Google Scholar]
  231. Smith S. A., Easton D. F., Ford D., Peto J., Anderson K., Averill D., Stratton M., Ponder M., Pye C., Ponder B. A. Genetic heterogeneity and localization of a familial breast-ovarian cancer gene on chromosome 17q12-q21. Am J Hum Genet. 1993 Apr;52(4):767–776. [PMC free article] [PubMed] [Google Scholar]
  232. Soini Y., Päkkö P., Nuorva K., Kamel D., Lane D. P., Vähäkangas K. Comparative analysis of p53 protein immunoreactivity in prostatic, lung and breast carcinomas. Virchows Arch A Pathol Anat Histopathol. 1992;421(3):223–228. doi: 10.1007/BF01611179. [DOI] [PubMed] [Google Scholar]
  233. Somerville J. E., Clarke L. A., Biggart J. D. c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma. J Clin Pathol. 1992 Jan;45(1):16–20. doi: 10.1136/jcp.45.1.16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  234. Spyratos F., Delarue J. C., Andrieu C., Lidereau R., Champème M. H., Hacène K., Brunet M. Epidermal growth factor receptors and prognosis in primary breast cancer. Breast Cancer Res Treat. 1990 Dec;17(2):83–89. doi: 10.1007/BF01806288. [DOI] [PubMed] [Google Scholar]
  235. Spyratos F., Hacene K., Tubiana-Hulin M., Pallud C., Brunet M. Prognostic value of estrogen and progesterone receptors in primary infiltrating ductal breast cancer. A sequential multivariate analysis of 1262 patients. Eur J Cancer Clin Oncol. 1989 Aug;25(8):1233–1240. doi: 10.1016/0277-5379(89)90420-3. [DOI] [PubMed] [Google Scholar]
  236. Srivastava S., Zou Z. Q., Pirollo K., Blattner W., Chang E. H. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature. 1990 Dec 20;348(6303):747–749. doi: 10.1038/348747a0. [DOI] [PubMed] [Google Scholar]
  237. Stanton P. D., Cooke T. G., Oakes S. J., Winstanley J., Holt S., George W. D., Murray G. D. Lack of prognostic significance of DNA ploidy and S phase fraction in breast cancer. Br J Cancer. 1992 Nov;66(5):925–929. doi: 10.1038/bjc.1992.387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  238. Tandon A. K., Clark G. M., Chamness G. C., Ullrich A., McGuire W. L. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol. 1989 Aug;7(8):1120–1128. doi: 10.1200/JCO.1989.7.8.1120. [DOI] [PubMed] [Google Scholar]
  239. Teare M. D., Santibáez-Koref M. F., Wallace S. A., White G. R., Evans D. G., Burnell L. D., Harris M., Howell A., Birch J. M. A linkage study in seven breast cancer families. Am J Hum Genet. 1993 Apr;52(4):786–788. [PMC free article] [PubMed] [Google Scholar]
  240. Tervahauta A., Eskelinen M., Syrjänen S., Lipponen P., Pajarinen P., Syrjänen K. Immunohistochemical demonstration of c-erb B-2 oncoprotein expression in female breast cancer and its prognostic significance. Anticancer Res. 1991 Sep-Oct;11(5):1677–1681. [PubMed] [Google Scholar]
  241. Theillet C., Le Roy X., De Lapeyrière O., Grosgeorges J., Adnane J., Raynaud S. D., Simony-Lafontaine J., Goldfarb M., Escot C., Birnbaum D. Amplification of FGF-related genes in human tumors: possible involvement of HST in breast carcinomas. Oncogene. 1989 Jul;4(7):915–922. [PubMed] [Google Scholar]
  242. Thor A. D., Moore DH I. I., Edgerton S. M., Kawasaki E. S., Reihsaus E., Lynch H. T., Marcus J. N., Schwartz L., Chen L. C., Mayall B. H. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst. 1992 Jun 3;84(11):845–855. doi: 10.1093/jnci/84.11.845. [DOI] [PubMed] [Google Scholar]
  243. Thor A. D., Schwartz L. H., Koerner F. C., Edgerton S. M., Skates S. J., Yin S., McKenzie S. J., Panicali D. L., Marks P. J., Fingert H. J. Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up. Cancer Res. 1989 Dec 15;49(24 Pt 1):7147–7152. [PubMed] [Google Scholar]
  244. Thorlacius S., Börresen A. L., Eyfjörd J. E. Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor. Cancer Res. 1993 Apr 1;53(7):1637–1641. [PubMed] [Google Scholar]
  245. Thorpe S. M., Rochefort H., Garcia M., Freiss G., Christensen I. J., Khalaf S., Paolucci F., Pau B., Rasmussen B. B., Rose C. Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res. 1989 Nov 1;49(21):6008–6014. [PubMed] [Google Scholar]
  246. Toguchida J., Yamaguchi T., Dayton S. H., Beauchamp R. L., Herrera G. E., Ishizaki K., Yamamuro T., Meyers P. A., Little J. B., Sasaki M. S. Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. N Engl J Med. 1992 May 14;326(20):1301–1308. doi: 10.1056/NEJM199205143262001. [DOI] [PubMed] [Google Scholar]
  247. Toi M., Kashitani J., Tominaga T. Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int J Cancer. 1993 Sep 30;55(3):371–374. doi: 10.1002/ijc.2910550305. [DOI] [PubMed] [Google Scholar]
  248. Toikkanen S., Helin H., Isola J., Joensuu H. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol. 1992 Jul;10(7):1044–1048. doi: 10.1200/JCO.1992.10.7.1044. [DOI] [PubMed] [Google Scholar]
  249. Tokunaga Y., Urano T., Furukawa K., Kondo H., Kanematsu T., Shiku H. Reduced expression of nm23-H1, but not of nm23-H2, is concordant with the frequency of lymph-node metastasis of human breast cancer. Int J Cancer. 1993 Aug 19;55(1):66–71. doi: 10.1002/ijc.2910550113. [DOI] [PubMed] [Google Scholar]
  250. Tora L., White J., Brou C., Tasset D., Webster N., Scheer E., Chambon P. The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell. 1989 Nov 3;59(3):477–487. doi: 10.1016/0092-8674(89)90031-7. [DOI] [PubMed] [Google Scholar]
  251. Trudel M., Mulligan L., Cavenee W., Margolese R., Côté J., Gariépy G. Retinoblastoma and p53 gene product expression in breast carcinoma: immunohistochemical analysis and clinicopathologic correlation. Hum Pathol. 1992 Dec;23(12):1388–1394. doi: 10.1016/0046-8177(92)90059-c. [DOI] [PubMed] [Google Scholar]
  252. Tsuda H., Hirohashi S., Shimosato Y., Hirota T., Tsugane S., Yamamoto H., Miyajima N., Toyoshima K., Yamamoto T., Yokota J. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1. Cancer Res. 1989 Jun 1;49(11):3104–3108. [PubMed] [Google Scholar]
  253. Tsuda H., Iwaya K., Fukutomi T., Hirohashi S. p53 mutations and c-erbB-2 amplification in intraductal and invasive breast carcinomas of high histologic grade. Jpn J Cancer Res. 1993 Apr;84(4):394–401. doi: 10.1111/j.1349-7006.1993.tb00149.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  254. Tubiana M., Pejovic M. H., Koscielny S., Chavaudra N., Malaise E. Growth rate, kinetics of tumor cell proliferation and long-term outcome in human breast cancer. Int J Cancer. 1989 Jul 15;44(1):17–22. doi: 10.1002/ijc.2910440104. [DOI] [PubMed] [Google Scholar]
  255. Têtu B., Brisson J. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy. Cancer. 1994 May 1;73(9):2359–2365. doi: 10.1002/1097-0142(19940501)73:9<2359::aid-cncr2820730919>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  256. Ullrich A., Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell. 1990 Apr 20;61(2):203–212. doi: 10.1016/0092-8674(90)90801-k. [DOI] [PubMed] [Google Scholar]
  257. Varley J. M., Armour J., Swallow J. E., Jeffreys A. J., Ponder B. A., T'Ang A., Fung Y. K., Brammar W. J., Walker R. A. The retinoblastoma gene is frequently altered leading to loss of expression in primary breast tumours. Oncogene. 1989 Jun;4(6):725–729. [PubMed] [Google Scholar]
  258. Varley J. M., Brammar W. J., Lane D. P., Swallow J. E., Dolan C., Walker R. A. Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas. Oncogene. 1991 Mar;6(3):413–421. [PubMed] [Google Scholar]
  259. Varley J. M., Swallow J. E., Brammar W. J., Whittaker J. L., Walker R. A. Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. Oncogene. 1987;1(4):423–430. [PubMed] [Google Scholar]
  260. Venter D. J., Tuzi N. L., Kumar S., Gullick W. J. Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification. Lancet. 1987 Jul 11;2(8550):69–72. doi: 10.1016/s0140-6736(87)92736-x. [DOI] [PubMed] [Google Scholar]
  261. Vielh P., Chevillard S., Mosseri V., Donatini B., Magdelenat H. Ki67 index and S-phase fraction in human breast carcinomas. Comparison and correlations with prognostic factors. Am J Clin Pathol. 1990 Dec;94(6):681–686. doi: 10.1093/ajcp/94.6.681. [DOI] [PubMed] [Google Scholar]
  262. Vignon F., Capony F., Chambon M., Freiss G., Garcia M., Rochefort H. Autocrine growth stimulation of the MCF 7 breast cancer cells by the estrogen-regulated 52 K protein. Endocrinology. 1986 Apr;118(4):1537–1545. doi: 10.1210/endo-118-4-1537. [DOI] [PubMed] [Google Scholar]
  263. Visscher D. W., Sarkar F. H., Wykes S., Kothari K., Macoska J., Crissman J. Clinicopathologic significance of p53 immunostaining in adenocarcinoma of the breast. Arch Pathol Lab Med. 1993 Oct;117(10):973–976. [PubMed] [Google Scholar]
  264. Visscher D. W., Smilanetz S., Drozdowicz S., Wykes S. M. Prognostic significance of image morphometric microvessel enumeration in breast carcinoma. Anal Quant Cytol Histol. 1993 Apr;15(2):88–92. [PubMed] [Google Scholar]
  265. Vogelstein B., Kinzler K. W. p53 function and dysfunction. Cell. 1992 Aug 21;70(4):523–526. doi: 10.1016/0092-8674(92)90421-8. [DOI] [PubMed] [Google Scholar]
  266. Vojtesek B., Fisher C. J., Barnes D. M., Lane D. P. Comparison between p53 staining in tissue sections and p53 proteins levels measured by an ELISA technique. Br J Cancer. 1993 Jun;67(6):1254–1258. doi: 10.1038/bjc.1993.234. [DOI] [PMC free article] [PubMed] [Google Scholar]
  267. Walker R. A., Dearing S. J., Lane D. P., Varley J. M. Expression of p53 protein in infiltrating and in-situ breast carcinomas. J Pathol. 1991 Nov;165(3):203–211. doi: 10.1002/path.1711650303. [DOI] [PubMed] [Google Scholar]
  268. Walker R. A., Gullick W. J., Varley J. M. An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer. Br J Cancer. 1989 Sep;60(3):426–429. doi: 10.1038/bjc.1989.299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  269. Walker R. A., Varley J. M. The molecular pathology of human breast cancer. Cancer Surv. 1993;16:31–57. [PubMed] [Google Scholar]
  270. Wang N. P., To H., Lee W. H., Lee E. Y. Tumor suppressor activity of RB and p53 genes in human breast carcinoma cells. Oncogene. 1993 Feb;8(2):279–288. [PubMed] [Google Scholar]
  271. Wen D., Peles E., Cupples R., Suggs S. V., Bacus S. S., Luo Y., Trail G., Hu S., Silbiger S. M., Levy R. B. Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. Cell. 1992 May 1;69(3):559–572. doi: 10.1016/0092-8674(92)90456-m. [DOI] [PubMed] [Google Scholar]
  272. Wilbur D. C., Barrows G. H. Estrogen and progesterone receptor and c-erbB-2 oncoprotein analysis in pure in situ breast carcinoma: an immunohistochemical study. Mod Pathol. 1993 Mar;6(2):114–120. [PubMed] [Google Scholar]
  273. Winstanley J., Cooke T., Murray G. D., Platt-Higgins A., George W. D., Holt S., Myskov M., Spedding A., Barraclough B. R., Rudland P. S. The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer. 1991 Mar;63(3):447–450. doi: 10.1038/bjc.1991.103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  274. Wintzer H. O., Zipfel I., Schulte-Mönting J., Hellerich U., von Kleist S. Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer. 1991 Jan 15;67(2):421–428. doi: 10.1002/1097-0142(19910115)67:2<421::aid-cncr2820670217>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  275. Wright C., Angus B., Nicholson S., Sainsbury J. R., Cairns J., Gullick W. J., Kelly P., Harris A. L., Horne C. H. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res. 1989 Apr 15;49(8):2087–2090. [PubMed] [Google Scholar]
  276. Yamashita H., Kobayashi S., Iwase H., Itoh Y., Kuzushima T., Iwata H., Itoh K., Naito A., Yamashita T., Masaoka A. Analysis of oncogenes and tumor suppressor genes in human breast cancer. Jpn J Cancer Res. 1993 Aug;84(8):871–878. doi: 10.1111/j.1349-7006.1993.tb02060.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  277. Yu H. R., Schultz R. M. Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes. Cancer Res. 1990 Dec 1;50(23):7623–7633. [PubMed] [Google Scholar]
  278. Zhou D. J., Ahuja H., Cline M. J. Proto-oncogene abnormalities in human breast cancer: c-ERBB-2 amplification does not correlate with recurrence of disease. Oncogene. 1989 Jan;4(1):105–108. [PubMed] [Google Scholar]
  279. van de Vijver M. J., Peterse J. L., Mooi W. J., Wisman P., Lomans J., Dalesio O., Nusse R. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med. 1988 Nov 10;319(19):1239–1245. doi: 10.1056/NEJM198811103191902. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Molecular Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES